00:00 , Aug 11, 2018 |  BioCentury  |  Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
17:15 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the...
12:01 , Aug 2, 2018 |  BC Extra  |  Clinical News

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the...
08:00 , Dec 3, 2015 |  BC Innovations  |  Targets & Mechanisms

The two faces of LTA4H

Although the enzyme LTA4H has long been considered a driver of inflammatory diseases, companies have yet to create an inhibitor that succeeds in the clinic beyond Phase II. That could be due to a secondary,...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Financial News

Celtaxsys Inc. completes venture financing

Celtaxsys Inc. , Atlanta, Ga.   Business: Pulmonary, Dermatology   Date completed: 2015-06-08   Type: Venture financing   Raised: $40 million   Investors: Domain Associates; Lumira Capital; RMI Partners; Masters Capital; Georgia Research Alliance Venture...
07:00 , Jun 15, 2015 |  BioCentury  |  Finance

Domain finds unmet need in CF

Domain Associates has decided the best way to play the cystic fibrosis space is to find a molecule that can be combined with the ever-increasing number of cocktails emerging from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). To...
02:10 , Jun 9, 2015 |  BC Extra  |  Financial News

Celtaxsys raises $40 million series D

Celtaxsys Inc. (Atlanta, Ga.) raised $40 million in a series D round led by Domain Associates, which invested through its Fund VIII. Also participating were Lumira Capital; RMI Partners; Masters Capital Management; and the Georgia...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

CTX-4430: Phase II started

Celtaxsys began a double-blind, placebo-controlled, Australian and New Zealand Phase II trial to evaluate 100 mg oral CTX-4430 once daily for 12 weeks in about 156 patients. Celtaxsys Inc. , Atlanta, Ga.   Product: CTX-4430...
07:00 , Apr 10, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Leukotriene A4 hydrolase (LTA4H) Structure-based design studies led to an LTA4H inhibitor that could be useful as a lead for new anti-inflammatory agents. LTA4H...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

CTX-4430: Phase I started

Celtaxsys began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate 4 dose levels of oral CTX-4430 once daily for 15 days in about 36 patients. Celtaxsys acquired the compound from Estrellita Pharmaceuticals Inc. (Belmont,...